Jerad Wagner, PA
Physician Assistant · Ardmore, OKNPI 1932448347
Payments from drug & device makers
Across 282 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$620
- AstraZeneca$533
- Lilly USA, LLC$513
- Bayer$458
- Sanofi-aventis U.S. LLC$425
- Novo Nordisk$387
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 54 | $620 |
| AstraZeneca | 30 | $533 |
| Lilly USA, LLC | 38 | $513 |
| Bayer | 42 | $458 |
| Sanofi-aventis U.S. LLC | 24 | $425 |
| Novo Nordisk | 24 | $387 |
| AbbVie | 15 | $278 |
| Insulet Corporation | 4 | $249 |
| Boehringer Ingelheim | 8 | $138 |
| Xeris Pharmaceuticals, Inc. | 6 | $113 |
| Merck | 5 | $68 |
| Amgen | 4 | $62 |
| Pfizer | 3 | $52 |
| Antares Pharma, Inc. | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Halozyme Inc | 2 | $36 |
| Abbott | 2 | $36 |
| Mylan Specialty L.p. | 2 | $34 |
| Exact Sciences | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
How this compares
$4,294 in reported general payments places this provider in the 90th percentile of 1,491 physician assistant providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 175 | $159,586 |
| JardianceEmpagliflozin | 118 | $153,099 |
| EliquisApixaban | 151 | $136,632 |
| OzempicSemaglutide | 55 | $77,146 |
| FarxigaDapagliflozin Propanediol | 65 | $72,712 |
| TrulicityDulaglutide | 34 | $60,107 |
| MounjaroTirzepatide | 43 | $45,211 |
| LinzessLinaclotide | 35 | $38,876 |
| KerendiaFinerenone | 33 | $33,418 |
| JanuviaSitagliptin Phosphate | 19 | $31,542 |
| MyrbetriqMirabegron | 31 | $18,209 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $17,290 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $16,481 |
| XareltoRivaroxaban | 15 | $14,889 |
| EntrestoSacubitril/Valsartan | 16 | $13,955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $620 | $187,938236 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $138 | $162,260137 claims |
| PfizerEliquis | $52 | $136,632151 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $513 | $105,31777 claims |
| Novo NordiskOzempic | $387 | $77,14655 claims |
| AstraZenecaFarxiga | $533 | $72,71265 claims |
| MerckJanuvia, Belsomra | $68 | $39,78939 claims |
| AbbVieLinzess | $278 | $38,87635 claims |
| BayerKerendia | $458 | $33,41833 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $18,20931 claims |
| Johnson & JohnsonXarelto | $26 | $14,88915 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $425 | $11,24013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,491 physician assistant providers in Oklahoma.
Other physician assistant in Ardmore
- Shelby LucasArdmore$10K
- Robert HannaArdmore$8K
- Eric CampbellEdmond$246K
- Katherine DemersEl Reno$146K
- Jennifer SmithOklahoma City$134K
- Christy NiehuesMustang$28K
- Matthew PattonTulsa$24K
- Sarah HawkOklahoma City$23K
- Gavin ChristieEdmond$19K
- Michelle GreenTulsa$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.